79 research outputs found
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
To determine whether MDR1 reversal by the addition of the P-glycoprotein
(P-gp) inhibitor PSC-833 to standard induction chemotherapy would improve
event-free survival (EFS), 419 untreated patients with acute myeloid
leukemia (AML) aged 60 years and older were randomized to receive 2
induction cycles of daunorubicin and cytarabine with or without PSC-833.
Patients in complete remission were then given 1 consolidation cycle
without PSC-833. Neither complete response (CR) rate (54% versus 48%; P =
.22), 5-year EFS (7% versus 8%; P = .53), disease-free survival (DFS; 13%
versus 17%; P = .06) nor overall survival (OS; 10% in both arms; P = .52)
were significantly improved in the PSC-833 arm. An integrated P-gp score
(IPS) was determined based on P-gp function and P-gp expression in AML
cells obtained prior to treatment. A higher IPS was associated with a
significantly lower CR rate and worse EFS and OS. There was no significant
interaction between IPS and treatment arm with respect to CR rate and
survival, indicating also a lack of benefit of PSC-833 in P-gp-positive
patients. The role of strategies aimed at inhibitory P-gp and other
drug-resistance mechanisms continues to be defined in the treatment of
patients with AML
Relapse After Allogeneic Bone-marrow Transplantation for Philadelphia-chromosome Positive Chronic Myeloid-leukemia - Cytogenetic Analysis of 24 Patients
Chromosome-studies in Patients With Philadelphia Chromosome-positive Chronic Myeloid-leukemia Submitted To Bone-marrow Transplantation - Results of a European Cooperative Study
Sweet's syndrome and myelodysplastic syndrome in a patient with metastatic breast carcinoma.
Diffuse biliary tract involvement mimicking primary sclerosing cholangitis after bone marrow transplantation.
Long-term Culture of Bone-marrow Autografts for Acute Myeloid-leukemia - In-vitro Hematopoietic Defect and Lack of Correlation With the Speed of Engraftment
Peripheral blood stem cells contamination in diffuse large cell (DLCL) and mantle cell (MCL) lymphomas: A quantitative comparison.
2-Chlorodeoxyadenosine therapy in Waldenstrom's macroglobulinaemia.
Despite some encouraging first results, experience with 2-chlorodeoxyadenosine (CdA) in the treatment of Waldenström's macroglobulinaemia (WM) has not as yet been very extensive. The present paper reports a clinical trial of the use of CdA in 18 patients having previously treated (n = 13) or untreated (n = 5) WM. CdA was administered by continuous intravenous infusion at a dose of 4 mg/m2/day for 7 days (5 patients) or as 2-h intravenous infusions at a dose of 5.6 mg/m2/day for 5 days (13 patients). Partial response was obtained in 7 cases. In this small series, no correlation could be found between response to CdA and patient characteristics at inclusion. During the first course of therapy, grade 4 neutropenia (< 0.5 x 10(9)/L) and thrombocytopenia (< 25 x 10(9)/L) developed in respectively 4 and 6 cases. In comparison with earlier reports haematological toxicity was more severe and the overall response rate lower in the present series of patients.Clinical TrialJournal Articleinfo:eu-repo/semantics/publishe
- …